← Back to Search

Continuous Glucose Monitoring

Dexcom CGM for Type 2 Diabetes in Long-term Care

Q: What is the magnitude of subjects involved in this clinical examination?

<p>Affirmative. According to records hosted on clinicaltrials.gov, this medical trial is currently accepting volunteers for participation. It was posted initially on April 19th 2021 and the most recent update took place May 6th 2021; with the aim of recruiting 100 patients from two different sites.</p>

Q: Is recruitment currently happening for this scientific experiment?

<p>According to the details available on clinicaltrials.gov, this investigation is currently recruiting participants. The original post date was April 19th in 2021 and it has been recently updated on May 6th of the same year.</p>

N/A

Waitlist Available

Led By Guillermo Umpierrez

Research Sponsored by Emory University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up during hospitalization (up to 60 days of admission)

Awards & highlights

Study Summary

This trial will test whether a wearable Dexcom CGM with Glucose Telemetry System (CGM-GTS) can help manage diabetes and reduce the risk of hypoglycemia in patients with T2D in long-term care facilities, compared to the current standard of care.

Eligible Conditions

Type 2 Diabetes
Diabetes

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ during hospitalization (up to 60 days of admission)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~during hospitalization (up to 60 days of admission)

This trial's timeline: 3 weeks for screening, Varies for treatment, and during hospitalization (up to 60 days of admission) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Number of Participants Experiencing Clinically Significant Hypoglycemia (BG<54 mg/dL)

Number of Participants Experiencing Hypoglycemia (BG<70 mg/dL)

Time in Range (TIR) Between 70-180 mg/dL

Secondary outcome measures

Glycemic Variability Calculated by Mean Amplitude of Glycemic Excursions (MAGE)

Number of Events of Hyperglycemia > 180 mg/dL

Number of Events of Hyperglycemia > 240 mg/dL

+10 more

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Dexcom CGM with Glucose Telemetry System (CGM-GTS)Experimental Treatment1 Intervention

Patients in the intervention CGM study arm will have a single daily fasting POC testing and will wear a real-time Dexcom G6 with GTS, and providers will adjust oral or insulin therapy based on CGM-GTS profile information.

Group II: POC testing with Blinded CGM (Standard of Care)Active Control1 Intervention

Patients in the standard of care study arm will wear a blinded CGM and receive POC testing before meals and bedtime, with providers adjusting oral agents or insulin dose based on POC results.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Dexcom G6 CGM with GTS

2021

N/A

~100

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

DexCom, Inc.Industry Sponsor

137 Previous Clinical Trials

29,750 Total Patients Enrolled

Emory UniversityLead Sponsor

1,636 Previous Clinical Trials

2,560,473 Total Patients Enrolled

Guillermo UmpierrezPrincipal Investigator - Emory University

Emergency Care of Atlanta Inc, Grady Memorial Hospital

University De Guayaquil (Medical School)

Emory University Hospital (Residency)

Media Library

Dexcom G6 CGM with CTS (Continuous Glucose Monitoring) Clinical Trial Eligibility Overview. Trial Name: NCT04818242 — N/A

Type 2 Diabetes Research Study Groups: POC testing with Blinded CGM (Standard of Care), Dexcom CGM with Glucose Telemetry System (CGM-GTS)

Type 2 Diabetes Clinical Trial 2023: Dexcom G6 CGM with CTS Highlights & Side Effects. Trial Name: NCT04818242 — N/A

Dexcom G6 CGM with CTS (Continuous Glucose Monitoring) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04818242 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What key outcomes is the research team expecting to observe?

"The primary aim of this study, evaluated during up to 60 days of hospitalization, is to quantify the number of hypoglycemic episodes (<70 mg/dl). Secondary goals include assessing glycaemic variability using MAGE (Mean Amplitude Glycemic Excursions), recording time spent in hypoglycemia per day and night between POC testing group and CGM-GTS group, as well as counting removed sensors for imaging or other procedures."

Answered by AI

What is the magnitude of subjects involved in this clinical examination?

"Affirmative. According to records hosted on clinicaltrials.gov, this medical trial is currently accepting volunteers for participation. It was posted initially on April 19th 2021 and the most recent update took place May 6th 2021; with the aim of recruiting 100 patients from two different sites."

Answered by AI

Is recruitment currently happening for this scientific experiment?

"According to the details available on clinicaltrials.gov, this investigation is currently recruiting participants. The original post date was April 19th in 2021 and it has been recently updated on May 6th of the same year."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Dexcom Continuous Glucose Monitoring in Long-term Care

Guillermo Umpierrez 2021. "Dexcom Continuous Glucose Monitoring in Long-term Care". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04818242.